Literature DB >> 28342378

Elevated triglyceride levels are associated with cognitive impairments among patients with major depressive disorder.

Tian Nan Shao1, Guang Zhong Yin2, Xiao Li Yin3, Jing Qin Wu2, Xiang Dong Du2, Hong Liang Zhu2, Jia Hong Liu3, Xiao Qiong Wang3, Dong Wu Xu4, Wen Jie Tang5, Li Hui6.   

Abstract

BACKGROUND: Cognitive deficits have been identified as one of core clinical symptoms of major depressive disorder (MDD). Accumulating evidence indicated that triglycerides (TG) might be associated with MDD and cognitive decline.
OBJECTIVE: This study examined whether patients with MDD had poorer cognitive functions than healthy controls, and further investigate whether TG levels were involved in MDD, and its cognitive impairments in a Han Chinese population.
METHOD: 115 patients with MDD and 119 healthy controls were enrolled. Cognitive functions were assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and serum TG levels were examined using enzymatic colorimetry.
RESULTS: TG levels were higher in patients with MDD than healthy controls after controlling for the variables. Cognitive test scores were lower in patients with MDD than healthy controls except for visuospatial/constructional index after controlling for the variables. TG levels were negatively correlated with visuospatial/constructional score, delayed memory score and RBANS total score of MDD. Further multivariate regression analysis showed that TG levels were negatively associated with visuospatial/constructional score, attention score, delayed memory score and RBANS total score of MDD.
CONCLUSIONS: Our findings supported that serum TG levels might be involved in MDD, and play an important role in cognitive impairments of MDD, especially in delayed memory. Moreover, patients with MDD experienced greater cognitive impairments than healthy controls except for visuospatial/constructional index.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28342378     DOI: 10.1016/j.comppsych.2017.03.007

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  6 in total

1.  Cognitive Impairments in First-Episode Drug-Naïve Versus Medicated Depressive Patients: RBANS in a Chinese Population.

Authors:  Qiu Fang Jia; Peng Chen; Hong Liang Zhu; Shan Shan Chen; Xiao Chu Gu; Xu Yuan Yin; Yan Hai Wu; Guang Zhong Yin; Li Hui
Journal:  Psychiatr Q       Date:  2019-09

2.  The SNP43 (G/A) polymorphism in CAPN10 gene confers an increased risk of cognitive impairment in cerebral small vessel disease.

Authors:  Kai Wu; Ying Cai
Journal:  J Clin Lab Anal       Date:  2018-07-16       Impact factor: 2.352

3.  Prospective plasma lipid profiling in individuals with and without depression.

Authors:  Dietmar Enko; Wolfgang Brandmayr; Gabriele Halwachs-Baumann; Wolfgang J Schnedl; Andreas Meinitzer; Gernot Kriegshäuser
Journal:  Lipids Health Dis       Date:  2018-06-26       Impact factor: 3.876

4.  Associations of the metabolic syndrome and its components with cognitive impairment in older adults.

Authors:  Insa Feinkohl; Jürgen Janke; Daniel Hadzidiakos; Arjen Slooter; Georg Winterer; Claudia Spies; Tobias Pischon
Journal:  BMC Geriatr       Date:  2019-03-07       Impact factor: 3.921

5.  Examining the Influence of Early Life Stress on Serum Lipid Profiles and Cognitive Functioning in Depressed Patients.

Authors:  Ágnes Péterfalvi; Nándor Németh; Róbert Herczeg; Tamás Tényi; Attila Miseta; Boldizsár Czéh; Maria Simon
Journal:  Front Psychol       Date:  2019-08-06

6.  The role of lipoprotein profile in depression and cognitive performance: a network analysis.

Authors:  Qiu-Fang Jia; Han-Xue Yang; Nan-Nan Zhuang; Xu-Yuan Yin; Zhen-Hua Zhu; Ying Yuan; Xiao-Li Yin; Yi Wang; Eric F C Cheung; Raymond C K Chan; Li Hui
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.